A: Connectivity between providers is a key component to the DSRIP program, as it will better serve the population
These trials are evaluating retatrutide across several patient populations, including individuals with obesity, type 2 diabetes, and related metabolic conditions
Read the Full Research Overview
All participants provided written informed consent and were cleared for participation by passing a mandatory medical screening
Improved metabolic flexibility: GLP-1RA improves insulin sensitivity, enabling the body to more efficiently utilize fat for energy during fasting and glucose for energy during feeding, thereby enhancing metabolic flexibility and reducing the risk of metabolic disorders
Alternative Approaches: Sequential or Single-Agent Therapy Rather than combining weight loss medications, evidence-based practice supports sequential therapy or optimised single-agent treatment as safer and more practical approaches to weight management